A&S Researchers Excited by MU Research Reactor Announcement
The recently announced agreement between the University of Missouri Research Reactor (MURR®) and AAA, Advanced Accelerator Applications International, SA (AAA), a Novartis company, holds distinct significance for the College of Arts and Science.
Recently Carolyn Anderson, PhD, joined A&S’s Chemistry Department as the Simón-Ellebracht Chair in Medicinal Chemistry to lead a new center specifically designed to research and discover radiopharmaceutical cancer treatments. The Molecular Imaging and Theranostics Center (MITC) will be a hub for discovery of novel radiolabeled agents that can see and/or treat cancer.
Dr. Anderson, who is also a professor in the Department of Radiology in the University of Missouri’s School of Medicine, brings more than 30 years of experience as an accomplished researcher in the Theranostics field. Her lab performed early research on two agents that were FDA-approved in the past 3 years and are commercially available for imaging (64Cu-dotatate) and treating neuroendocrine tumors (lutetium Lu 177 dotatate ).
“This exciting agreement certainly helps shine an international spotlight on the research we are doing at the University of Missouri, at MURR, MITC and many other research centers across campus,” said Dr. Anderson. “It also provides opportunities to discover additional avenues for collaboration.”
MITC is a hub for research collaborators throughout the MU campus. It also fosters collaboration with other strategic entities in Missouri and beyond. Additionally, MITC identifies both small and large industry partners to brainstorm and perform pre-clinical studies that set the stage for translation into first-in-human studies.
“The College of Arts and Science views the University of Missouri’s focus on Precision Health research as a top priority,” said Pat Okker, Dean of the College of Arts and Science. “The research plans currently underway at MITC and other A&S entities like the Chemistry Department play a key role in many Precision Health discoveries. We’re looking forward to seeing how this important collaboration will move those discoveries forward.”